A landmark clinical trial reports that a breath-based test detected lung cancer with over 90% accuracy, aiming to address the persistent gap between symptom onset and diagnosis. With lung cancer often identified at advanced stages, a minimally invasive test could shift screening and triage workflows if validated in broader populations. While the study details in the provided summary emphasize performance, the next step for the field remains determining how the signal behaves across histologies, comorbidities, and real-world settings where confounders can reduce test specificity.